Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Mirum Pharmaceuticals, Inc.

NASDAQ: MIRM · Life Sciences · 9 alerts · CIK 1759425

Mirum Pharmaceuticals, Inc. stories on ALFA USA NewsRead the news →
Share price
$91.58Close, Nov 16
Market cap
$5.98B
Shares outstanding
65.28MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Mirum Pharmaceuticals, Inc. filings on SEC EDGAR ↗

7:42 AM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced that its Phase 3 AZURE-4 study of brelovitug met its primary endpoint in patients with chronic hepatitis delta virus (HDV). The study showed that 59% of patients on the 300 mg weekly dose achieved the combined endpoint of virologic response and ALT normalization compared to 0% in the delayed-treatment arm. This data, alongside results from the AZURE-1 study, will form the basis of the company's U.S. registration package for brelovitug.

4:47 PM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive results from Cohort 2 of its pivotal PROGRESS study evaluating ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 with fibrodysplasia ossificans progressiva (FOP). The study met its endpoints with a significant reduction in total heterotopic ossification lesion volume and improved joint mobility compared to placebo, supporting a planned sNDA submission in the first half of 2027.

8:09 AM ET 8-K
Clinical Trial Data

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.

8:04 AM ET 8-K
Regulatory Approval

Mirum Pharmaceuticals Regulatory Approval

The FDA has approved Mirum Pharmaceuticals' Atebrioz (zilurgisertib) for the treatment of fibrodysplasia ossificans progressiva (FOP) in patients aged 12 and older. The drug, licensed from Incyte, is a first-of-its-kind oral ALK2 inhibitor designed to reduce new heterotopic ossification (abnormal bone formation). Mirum expects the product to be commercially available in the U.S. in October 2026.

Counterparty
Incyte Corporation

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.